Divi's Laboratories Limited (DIVISLAB): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Divi's Laboratories Limited, explained in plain English.
- Divi's Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- DIVISLAB closed at ₹11,180.50 on 20 November 2026.
- Over the past year the shares are up 73.0%, trading between ₹5,647.50 and ₹11,824.00.
- Reported fundamentals show return on equity of 20.13%, a net margin of 27.59%, debt to equity of 0.03.
- Our Pulse grade checklist scores it A (96/100) across momentum, growth, profitability and safety on fixed thresholds.
- Annualised volatility over the past year is 25.31% with a maximum drawdown of -12.37% and a beta of 0.61 against NIFTY 50.
- Recent coverage: Pharma stocks under pressure; Laurus, Sai Life, Divi's slide up to 10%
- Recent coverage: Divi's Laboratories Market Cap Crosses Rs 3 Lakh Crore: What Is Driving The Rally
- Recent coverage: ICICI Bank, Divi's among 14 NSE 500 stocks hit new highs in Muhurat session
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Divi's Laboratories Limited (DIVISLAB)
₹11,180.5
▲ 2.5 (+0.02%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 5/51M
+23.04%
3M
+30.46%
6M
+62.20%
1Y
+73.01%
Where it sits in its 52-week range
93%Below 52-week high
3.3%
92.1% above the low
Momentum read
Strong
5/5 checks passed
52-wk high
₹11,565.5
52-wk low
₹5,821
Market cap
₹2,96,807 Cr
P/E (trailing)
88.2
Dividend yield
—
ROE
20.13%
Profit margin
27.59%
Revenue growth
35.4%
Price / Book
16.48
Debt / Equity
0.03
EPS (TTM)
126.72
Book value
₹678.52
Beta
0.61
Pulse grade: A, 96 out of 100
Momentum
A- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✓Positive 3-month return
Growth
A- ✓Revenue growth above 12%
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
A- ✓Return on equity above 18%
- ✓Return on equity above 12%
- ✓Profit margin above 12%
Safety
A- ✓Debt below 50
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹3,676 crore · net profit ₹1,127 crore · margin 30.7%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
| Peer | Price ₹ | Day change | From 52-wk high |
|---|---|---|---|
| SUNPHARMA | 1,884.9 | -0.79% | -5.81% |
| DRREDDY | 1,390.2 | -0.76% | -0.76% |
| CIPLA | 1,415 | -0.25% | -7.59% |
| APOLLOHOSP | 9,200 | +5.29% | 0.00% |
| LUPIN | 2,014 | +0.76% | -19.91% |
| AUROPHARMA | 1,799 | -0.37% | -3.03% |
DIVISLAB headlines
No DIVISLAB stories right now.
DIVISLAB filings & announcements
DIVISLAB, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
25.31%
Sharpe ratio
2.12
Sortino ratio
3.83
Max drawdown
-12.37%
Daily VaR (95%)
-2.28%
CAGR (1Y)
76.22%
Return skew
0.93
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.